These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27450106)

  • 1. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
    Gillessen S; Gilson C; James N; Adler A; Sydes MR; Clarke N;
    Eur Urol; 2016 Dec; 70(6):906-908. PubMed ID: 27450106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
    Bensimon L; Suissa S; Azoulay L
    Eur Urol; 2013 Aug; 64(2):e28. PubMed ID: 23619391
    [No Abstract]   [Full Text] [Related]  

  • 5. An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
    Zhu W; Xu H; Ma J; Guo J; Xue W; Gu B; Sheng L; Yao X; Sun F; Gong J; Qiu W; Ding Q; Jiang H
    Urol Int; 2017; 98(1):79-84. PubMed ID: 27684440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of androgen deprivation for prostate cancer: benefits versus side effects--a patient-physician dialogue.
    Soloway MS
    Urology; 2002 Nov; 60(5):735-7. PubMed ID: 12429286
    [No Abstract]   [Full Text] [Related]  

  • 7. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    Ranasinghe WKB; Williams S; Ischia J; Wetherell D; Baldwin G; Shulkes A; Sengupta S; Bolton D; Patel O
    BJU Int; 2019 May; 123 Suppl 5():36-42. PubMed ID: 31012989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
    Spratt DE; Zhang Z; Zelefsky MJ
    Eur Urol; 2013 Aug; 64(2):e29-30. PubMed ID: 23619389
    [No Abstract]   [Full Text] [Related]  

  • 9. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
    Ohlmann CH
    Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-deprivation therapy for prostate cancer.
    Higano C
    Clin Prostate Cancer; 2003 Jun; 2(1):22-3. PubMed ID: 15046679
    [No Abstract]   [Full Text] [Related]  

  • 12. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
    García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
    Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined androgen blockade for the treatment of metastatic cancer of the prostate.
    Schellhammer PF
    Urology; 1996 May; 47(5):622-8. PubMed ID: 8650856
    [No Abstract]   [Full Text] [Related]  

  • 16. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conservative therapy of prostate cancer].
    Leitenberger A; Altwein JE
    Fortschr Med; 1991 Sep; 109(28):563-7. PubMed ID: 1721888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.